Outcome of Adult Patients with Acute Myeloid Leukemia who Failed to Achieve Complete Remission after one Course of Induction Chemotherapy: A Report from the BGMT Study Group: For the BGMT

References

• Rai K. R., Holland J. F., Glidewell O. J., Weinberg V., Brunner K., Obrecht J. P., Preisler H. D., Nawabi I. W., Prager D., Carey R. W., Cooper M. R., Haurani F., Hutchison J. L., Silver R. T., Falkson G., Wiernik P., Hoagland H. C., Bloomfield C. D., James G. W., Gottlieb A., Ramanan S. V., Blom J., Nissen N. I., Bank A., Ellison R. R., Kung E., Henry P., McLntyre O. R., Kaan S. K. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981; 58: 1203–12
   PubMed Web of Science ®Google Scholar
• Stone R., Mayer R. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematology/Oncology Clinics of North America 1993; 7: 47–64
   PubMed Web of Science ®Google Scholar
• Mayer R., Davis R., Schiffer C., Berg D., Powell B., Schulman P., Omura G., Moore J., McLntyre O., Frei I II, E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Rowe J. M., Andersen J. W., Mazza J. J., Bennett J. M., Paietta E., Hayes F. A., Oette D., Cassileth P. A., Stadtmauer E. A., Wiernik P. H. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastem Cooperative Oncology Group (E1490). Blood 1995; 86: 457–62
   PubMed Web of Science ®Google Scholar
• Viens P., Penault-Llorca F., Jacquemier J., Gravis G., Cowen D., Bertucci E., Houvenaeghel G., Blaise D., Maraninchi D. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplantation 1998; 21: 249–54
   PubMed Web of Science ®Google Scholar
• Hewlett J., Kopecky K. J., Head D., Eyre H. J., Elias L., Kingsbury L., Balcerzak S. P., Dabich L., Hynes H., Bickers J. N., Appelbaum F. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 1995; 9: 562–9
   PubMed Web of Science ®Google Scholar
• Weick J. K., Kopecky K. J., Appelbaum F. R., Head D. R., Kingsbury L. L., Balcerzak S. P., Bickers J. N., Hynes H. E., Welborn J. L., Simon S. R., Grever M. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–51
   PubMed Web of Science ®Google Scholar
• Vogler W., Velez-Garcia E., Weiner R., Flaum M., Bartolucci A., Omura G., Gerber M., Banks P. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Journal of Clinical Oncology 1992; 10: 1103–11
   PubMed Web of Science ®Google Scholar
• Wiernik P., Banks P., Case D., Arlin Z., Periman P., Todd M., Ritch P., Enck R., Weitberg A. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–9
   PubMed Web of Science ®Google Scholar
• Geller R. B., Burke P. J., Karp J. E., Humphrey R. L., Braine H. G., Tucker R. W., Fox M. G., Zahurak M., Morrell L., Hall K. L. A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989; 74: 1499–506
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Reece D. E., Shepherd J. D., Barnett M. J., Brown R. A., Frei-Lahr D. A., Klingemann H. G., Bolwell B. J., Spinelli J. J., Herzig R. H. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–35
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Matthews J. P., Young G. A., Szer J., Gillett A., Joshua D., Bradstock K., Enno A., Wolf M. M., Fox R. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–7
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Lowenthal R. M., Joshua D., Matthews J. P., Todd D., Cobcroft R., Whiteside M. G., Kronenberg H., Ma D., Dodds A. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27–32
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Matthews J. P., Young G. A., Bradstock K., Lowenthal R. M. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leukemia and Lymphoma 1998; 28: 315–27
   PubMed Web of Science ®Google Scholar
• Schiller G. Treatment of resistant acute myeloid leukemia. Blood Reviews 1991; 5: 220–6
   PubMed Web of Science ®Google Scholar
• Liso V., Iacopino P., Awisati G., Peru M. C., Broccia G., Carotenuto M., Falda M., Fazi P., Lazzarino M., Leoni P., Mirto S., Pucci G., Nobile F., Nosari A. M., Specchia G., Stasi R., Tabilio A., Mandelli F. Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne de l'Adulto. Leukemia 1996; 10: 1443–52
   PubMed Web of Science ®Google Scholar
• Anderlini P., Ghaddar H. M., Smith T. L., Pierce S., Kantarjian H. M., O'Brien S., Keating M. J., Freireich E. J., Estey E. H. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996; 10: 964–9
   PubMed Web of Science ®Google Scholar
• Reiffers J., Stoppa A. M., Attal M., Michallet M., Marit G., Blaise D., Huguet F., Corront B., Cony-Makhoul P., Montastruc M., Gastaut J. A., Laurent G., Molina L., Broustet A., Maraninchi D., Pris J., Hollard D., Faberes C. Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience. Nouvelle Revue Francaise d'Hematologie 1993; 35: 17–9
   PubMedGoogle Scholar
• Reiffers J., Stoppa A. M., Attal M., Michallet M., Marit G., Blaise D., Huguet F., Corront B., Cony-Makhoul P., Gastaut J. A., Laurent G., Molina L., Broustet A., Maraninchi D., Pris J., Hollard D., Faberes C. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874–82
   PubMed Web of Science ®Google Scholar
• Dastugue N., Payen C., Bernard P., Lafage M., Leroux D., Bertheas M., Baranger L., Attal M., Reiffers J., Blaise D., Sotto J., Harousseau J., Cahn J., Pignon B., Witz F. Prognostic impact of karyotype in acute myeloid leukemias allografted in first complete remission. An analysis of the BGMT and GOELAM trials. Proc ASH. 1998
   Google Scholar
• Kaplan E. L., Meier P. Non parametric estimation fom incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Peto R., Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185–98
   Web of Science ®Google Scholar
• Keating M. J., Smith T. L., Gehan E. A., McCredie K. B., Bodey G. P., Freireich E. J. A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia. Cancer 1982; 50: 457–65
   PubMed Web of Science ®Google Scholar
• Leith C. P., Willman C. L. Prognostic markers in acute leukemia. Current Opinion in Hematology 1996; 3: 329–34
   PubMedGoogle Scholar
• List A. F. Multidrug resistance: clinical relevance in acute leukemia. Oncology 1993; 7: 23–8
   PubMedGoogle Scholar
• Leith C. P., Kopecky K. J., Godwin J., McConnell T., Slovak M. L., Chen I. M., Head D. R., Appelbaum F. R., Willman C. L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–9
   PubMed Web of Science ®Google Scholar
• Casasnovas R. O., Solary E., Campos L., Maynadie M., Favre M., Bremend J. L., Garand R., Bene M. C., Faure G. Prognostic relevance of surface markers in adult de novo acute myeloblastic leukemias: a prospective study of the Groupe d'Etude Immunologique des Leucemies (G.E.I.L.). Leukemia and Lymphoma 1994; 13: 7–10
   PubMed Web of Science ®Google Scholar
• Sperling C., Buchner T., Creutzig U., Rifter J., Harbott J., Fonatsch C., Sauerland C., Mielcarek M., Maschmeyer G., Loffler H. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Leukemia and Lymphoma 1995; 17: 417–26
   PubMed Web of Science ®Google Scholar
• Dastugue N., Payen C., Lafage-Pochitaloff M., Bernard P., Leroux D., Huguet-Rigal F., Stoppa A. M., Marit G., Molina L., Michallet M., Maraninchi D., Attal M., Reiffers J. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995; 9: 1491–8
   PubMed Web of Science ®Google Scholar
• Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–33
   PubMed Web of Science ®Google Scholar
• Preisler H. Poor prognosis acute myelogenous leukemia. Leukemia and Lymphoma 1993; 9: 273–83
   PubMed Web of Science ®Google Scholar
• Bezwoda W., Bernasconi C., Hutchinson R., Winfield D., de Bock R., Mandelli F. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 1990; 66: 418–22
   PubMed Web of Science ®Google Scholar
• Rassam S. M., Turker A., Powles R. L., Smith A. G., Newland A. C., Erskine J. G., Pearce R. M., Goldstone A. H. Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience. Seminars in Oncology 1993; 20: 13–9
   PubMed Web of Science ®Google Scholar
• Schiller G., Lee M., Territo M., Gajewski J., Nimer S. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. American Journal of Hematology 1993; 43: 195–9
   PubMed Web of Science ®Google Scholar
• Spadea A., Petti M., Fazi P., Vegna M., Arcese W., Awisati G., Spiriti M., Latagliata R., Meloni G., Testi A., Amadori S., Mandelli F. Mitoxantrone, Etoposide and Intermediate-Dose Ara-C (MEC): An Effective Regimen for Poor Risk Acute Myeloid Leukemia. Leukemia 1993; 7: 549–52
   PubMed Web of Science ®Google Scholar
• Butturini A., Bortin M. M., Gale R. P. Graft versus leukemia following bone marrow transplantation. Bone Marrow Transplantation 1987; 2: 233–42
   PubMed Web of Science ®Google Scholar
• Horowitz M., Gale R., Sondel P., Goldman J., Kersey J., Kolb H., Rimm A., Ringden O., Rozman C., Speck B., Truitt R., Zwaan F., Bortin M. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–62
   PubMed Web of Science ®Google Scholar
• Berman E., Little C., Gee T., O'Reilly R., Clarkson B. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. New England Journal of Medicine 1992; 326: 156–60
   PubMed Web of Science ®Google Scholar
• Aversa F., Tabilio A., Velardi A., Cunningham I., Terenzi A., Falzetti F., Ruggeri L., Barbabietola G., Aristei C., Latini P., Reisner Y., Martelli M. F. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New England Journal of Medicine 1998; 339: 1186–93
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Boussiotis V. A., Neuberg D., Brennan L. L., Hirano N., Nadler L. M., Gribben J. G. Transplantation of anergic histoincompatible bone marrow allografts. New England Journal of Medicine 1999; 340: 1704–14
   PubMed Web of Science ®Google Scholar
• Sykes M., Preffer F., McAfee S., Saidman S. L., Weymouth D., Andrews D. M., Colby C., Sackstein R., Sachs D. H., Spitzer T. R. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755–9
   PubMed Web of Science ®Google Scholar